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Objectives: Our objective was to assess the short- and long-term outcome for patients after carotid body tumor (CBT)
resection and discuss the potential pitfalls of the treatment.
Methods: An analysis was undertaken of all patients who underwent CBT resection at Royal Brisbane and Women’s
Hospital and Greenslopes Private Hospital between 1982 and 2007. Primary tumor characteristics, surgical technique,
and outcomes were recorded and analyzed.
Results: A total of 49 consecutive CBT resections (2 recurrent tumors) were carried out in 39 patients (26 women [56%])
who were a mean age of 49 years (range, 17-75 years). A nontender neck mass was the presenting complaint in 85%,
followed by screening in familial or contralateral tumors in 26%. Familial cases occurred in 11 patients (28%). There were
no operative deaths. Complications occurred in 13 of the 49 operations (27%), predominantly temporary nerve palsies
and were more likely to occur in tumors of large volume or in cases of removal of coexisting vagal tumors. Malignant
disease was present in seven cases (15%). All patients have been followed-up postoperatively for a mean of 11 years (range,
2-26 years). Metachronous paragangliomas have been discovered in six patients, all with familial disease.
Conclusions: Early resection of carotid body tumors should be undertaken while still small to minimize the risk of
neural injury, which increases with tumor size. In cases of bilateral CBT, we recommend that the smaller tumor be
resected first, before the staged resection of the larger contralateral tumor. In familial or bilateral tumor cases, other
synchronous and metachronous paragangliomas should be excluded. Mandatory lifelong follow-up is essential.
( J Vasc Surg 2010;52:1518-24.)Paragangliomas of the neck are rare, with the most
common form being the carotid body tumor (CBT). The
carotid body is a small cluster of chemoreceptors and
supporting cells located near the carotid bifurcation that
was first anatomically described in 1743 by Albrecht von
Haller.1,2 The glomus cells of the carotid body are derived
from neural crest cell lines, which in turn are derived from
neuroectoderm. Although CBTs are rare tumors, diag-
nosed with an incidence of about 1:30,000 in the general
population,3 they account for 50% of head and neck
paragangliomas.4 It is generally considered that approxi-
mately 90% of CBTs are sporadic and 10% are familial.5 A
family history of paraganglioma syndrome should be con-
sidered in all cases but particularly if bilateral tumors exist.
Vagal paragangliomas (VP) are the other rarer form of
paragangliomas that the vascular surgeon might encounter
and account for 5% of all head and neck paragangliomas. In
this report, we review our experience with the clinical
From the Department of Vascular Surgery, Royal Brisbane and Women’s
Hospital;a and the Department of Surgery, University of Queensland
Centre for Clinical Research, University of Queensland.b
Competition of interest: none.
Correspondence: Allan J. Kruger, FRACS, MBBS, DDU, Royal Brisbane
and Women’s Hospital, Department of Vascular Surgery, Butterfield
St, Herston, Brisbane, Queensland, Australia (e-mail: allan_kruger@
health.qld.gov.au).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00
Copyright © 2010 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.06.153
1518presentation andmanagement of these tumors, with special
emphasis on the pitfalls in management that can occur and
insights learned from managing a sizable series of patients
during a 25-year period.
METHODS
All patients who underwent CBT resection of cervical
paragangliomas by vascular surgeons at the Royal Brisbane
and Women’s Hospital Vascular Unit and Greenslopes
PrivateHospital between 1982 and 2007were identified by
hospital admission codes and vascular unit audit data and
were cross-referenced to operative theater procedural
codes. All patients have been monitored from the time of
their tumor resection.
Patients and presenting symptoms. A total of 47
primary CBTs and 2 recurrent tumors were diagnosed in 39
patients (26 women [56%]) who were a mean age of 49
years (range, 17-75 years). All 49 tumors were histologi-
cally proven CBT. Six patients underwent VP resections
concurrently with the CBT procedure. Sporadic CBT were
found in 28 patients (72%), and 11 (28%) had familial CBT.
Bilateral tumors, which were found incidentally in most
cases, were seen in 14 patients (36%). These 39 patients
underwent 49 operative procedures, of which 47 proce-
dures were for primary tumors and 2 for recurrent disease.
Eight patients underwent staged bilateral CBT resection,
and a further four patients had previously undergone con-
tralateral CBT excision at other institutions.
The presenting symptoms for the 49 CBT in these 39
patients are listed in Table I and are tabulated for 41
patients presenting with CBTs alone, 6 patients with con-
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CBT. A number of patients presented with multiple symp-
toms. A neck mass was the most common initial presenting
complaint, evident in approximately two-thirds of patients
with primary tumors. If the patient whose paragangliomas
were detected by screening and the two recurrent CBTs are
excluded, this figure rises to 100% (31 of 31). This was
uniform across the 25 years of the study.
The mass was usually painless, although four patients
with CBT only (10%) reported pain associated with the
mass. Cranial nerve palsies, which in all cases were vagal
(XII) nerve palsies, were present in 10% of patients with
CBT alone and in one-third of patients with concurrent
CBT and VP. Although three patients (5%) presented with
palpitations or flushes, no CBT was hormonally functional
on the basis of endocrine studies that were undertaken
selectively in patients where there was a clinical suspicion.
Screening of family members identified 16 additional
tumors. Metastatic spread of the CBT was documented in
three patients (8%) at the time of initial presentation. A
confirmed histologic diagnosis of CBT was made at the
referring institution by fine-needle aspiration biopsy in four
cases. This delayed treatment in one patient by 13 years
because she had been warned of hemorrhagic risk with
surgery.
Four of the familial cases had undergone previous
surgery for their paraganglioma before presentation at our
unit. These patients represented two distinct families. The
other two family groups had not been diagnosed with other
paragangliomas before their initial CBT diagnosis at our
institution.
Investigations. The investigations undertaken in
these patients are listed in Table II. Many patients had
multiple investigations. Computed tomography angiogra-
phy (CTA) was the most commonly used imaging modal-
ity, followed by duplex ultrasound (DUS) imaging. An-
Table I. Presenting symptoms for 49 cervical
paragangliomas (in 39 patients) before surgical resection
Presenting symptom
CBT only CBT and VP
Recurrent
CBT
(n  41) (n  6) (n  2)
No. (%) No. (%) No. (%)
Mass 27 (66) 4 (66) 2 (100)
Screening 14 (34) 2 (33) 2 (100)
Pain 4 (10) . . . . . .
FNAB 4 (10) . . . . . .
Cranial nerve palsya 4 (10) 2 (33) 2 (100)
Dysphagia/dysphonia/SOB 3 (7) . . . . . .
Fainting 3 (7) . . . . . .
Metastasis 3 (7) . . . . . .
Palpitations 2 (5) . . . . . .
Flushes 2 (5) . . . . . .
Tinnitus 1 (2) 1 (17) . . .
CBT, Carotid body tumor; FNAB, fine-needle aspiration biopsy; SOB,
shortness of breath; VP, vagal paragangliomas.
aAll vagal nerve palsy.giography was used frequently in the early years in thisseries but is now rarely used, having been superseded by
CTA and DUS. No preoperative embolization was used.
Treatment. All patients were managed by surgical re-
section of the CBT, with most of the procedures performed
by a single surgeon. The intent of surgery was palliative in
the three patients who presented with metastatic disease
and curative in the remaining cases. At the time of surgery
in one patient, there was direct extension of tumor to the
base of the skull with bony erosion, and surgery was non-
curative in this case. This patient was offered adjuvant
radiotherapy but refused. The tumor mass enlarged to
again cause compressive symptoms 8 years later, and a
further debulking procedure was done. The patient was
once again offered radiotherapy and agreed.
All procedures were performed under general anesthe-
sia, and nasoendotracheal intubation was used liberally
when there were preoperative concerns about the cranial
extent of the tumor. One patient required emergency cri-
cothyroidotomy and formal tracheostomy before reopera-
tion for tumor resection because of the tumor size. A
second patient required tracheostomy after the resection of
a larger second CBT and vagal tumor; this was reversed
after 3 months.
The tumors were approached through a standard end-
arterectomy incision along the anterior border of the ster-
nocleidomastoid. As a general principle, CBT resection was
achieved using a craniocaudal approach with conventional
monopolar diathermy. In patients earlier in the series,
dissection was commenced at the bifurcation, but this was
modified to the above approach to avoid the arterial plexus
often present in the fork of the bifurcation and to avoid the
ascending pharyngeal branch of the external carotid artery,
which often tethers the tumor.
Early identification of neural structures is paramount.
In particular, the superior laryngeal nerve on the deep
aspect is best found from a posterolateral approach and the
hypoglossal nerve dissected from the peritumor fibrous
“capsule” superiorly. Early looping of the common carotid
artery (CCA) is followed by dissection at the cranial (distal)
extent of the internal carotid artery (ICA). If possible, the
tumor is then peeled down off the vessels with diathermy,
leaving the carotid bifurcation dissection until last.
The CBTs in this series were not routinely assigned a
Shamblin classification using preoperative imaging or the
intraoperative findings, and the retrospective nature of this
Table II. Diagnostic modalities used in the diagnosis of
47 primary carotid body tumors
Diagnostic modality No. (%)
Total tumors 47 (100)
Computed tomography angiography 40 (85)
Duplex ultrasound imaging 34 (72)
Digital subtraction angiography 19 (40)
Magnetic resonance arteriography 2 (4)
Fine-needle aspiration biopsy 4 (9)series makes post hoc classification hazardous. Neverthe-
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without the need for adjunctive operative procedures in 42
of the 49 (85%) operative cases. This could be consistent
with Shamblin group 1 or 2 tumors. The ICA and CCA
bifurcation was resected in five cases (10%). These cases
would be consistent with Shamblin group 3 tumors. An
Argyle shunt (Covidien, Mansfield, Mass) was used in
each of these five cases, and the ICA was reconstructed
using a reversed long saphenous vein interposition graft;
however, external carotid artery (ECA) reconstruction
was not done. In the final two cases, the ECA alone was
resected. There were no adverse effects from ECA resec-
tion without reconstruction.
Six patients underwent resection of VPs concurrently
with the CBT resection. Five of these were in patients with
familial cases of CBT. Enlarged or adherent lymph nodes
were resected for histology. Two operative cases required
transfusions, both in the same patient with an extremely
large CBT. At the initial operation, the styloid process
perforated the distal ICA at the skull base. Temporary
balloon occlusion was used for control while the artery was
repaired by simple suture. At reoperation 8 years later, the
CCA/ICA confluence was resected and a long saphenous
vein interposition graft was inserted. This procedure was
complicated by a postoperative anastomotic hemorrhage.
There were no operative deaths. Complications oc-
curred in 13 of the 49 operations (27%), and these are
summarized in Table III. Unplanned permanent cranial
nerve palsies occurred in six operations (12%), whereas a
further five (10%) resulted in temporary cranial nerve defi-
cits. These data exclude vagal palsies in the six patients who
underwent concurrent VP resection where vagal nerve palsy
Table III. Complications of 49 tumor resection
proceduresa
Complication
CBT Only CBT & VP
Recurrent
CBT
(n  41) (n  6) (n  2)
No.
(%)—P/T
No.
(%)—P/T
No.
(%)—P/T
Nerve injury
Vagal 5 (12)—3/2 6 (expected) . . .
Glossopharyngeal 1 (2)—1/0 . . . . . .
Hypoglossal 5 (12)—3/2 2 (33)—0/2 1 (50)—1/0
Facial (MMN) 2 (5)—0/2 . . . . . .
External laryngeal 1 (2)—1/0 . . . . . .
Labile blood
pressureb
4 (10)—0/4 1 (2)—0/1 —
Tracheostomyb 2 (5)—1/1 . . . . . .
Jaw ache 1 (2)—0/1 . . . . . .
Aspirationb 1 (2) . . . 1 (50)
Hemorrhage postop 1 (2) . . . 1 (50)
CBT,Carotid body tumor;MMN,marginal mandibular nerve; P, permanent
nerve palsy; T, temporary nerve palsy; VP, vagal paragangliomas.
aIn cases complicated by cranial nerve palsies, often more than one nerve was
affected.
bThese patients all had bilateral CBT resections, and the complication
occurred after resection of the second, contralateral CBT.was expected. Tumor volume, as measured by CT, wasassessed in 40 cases (85%). The excised CBTs had a mean
volume of 23.6 cm3 (range, 0.5-350 cm3). There was no
statistically significant difference between the volumes of
the pathologic specimens and the volumesmeasured onCT
(P  .1). The mean volume of the CBTs in the cases
resulting in nerve palsy was significantly larger than in those
procedures in which nerve palsy did not occur (52.2 v 16.1
cm3; P  .04).
Histologically proven CBT was seen in all 49 opera-
tions. In addition, VPs were confirmed in the six cases
where these were concurrently resected. Three cases had
microscopic lymph node spread and one had perivascular
spread. Direct extension of tumor into surrounding tissue
was seen in three cases at the level of the skull base. Two of
these patients had known metastatic disease.
Five patients received adjuvant radiotherapy. This in-
cluded the three patients who presented with metastatic
disease and one patient who had direct extension of
tumor to the base of skull with associated bony erosion.
A further patient had radiotherapy upon resection of a
recurrent CBT. Those patients with micrometastasis to
lymph nodes and positive soft-tissue margins were not
given adjuvant therapy. No tumor recurrence has been
seen during follow-up.
Three patients died from proven metastatic CBT dur-
ing follow-up (mean, 11 years; range, 2-26 years). Recur-
rent CBT developed in the neck in two of these patients
before death, and one underwent reoperation for debulk-
ing. Another patient required reoperation for recurrent
CBT 12 years after the primary resection and remains free
of further recurrence now 26 years after the initial resec-
tion.
New tumors have been diagnosed during follow-up in
six patients, at a mean interval of 5 years (range, 2-18 years)
after resection of their primary tumor. All these are familial
cases (Table IV).
DISCUSSION
This is a sizeable series of patients with cervical para-
gangliomas (39 patients, 49 procedures) who have been
managed during a 25-year period, predominantly by one
vascular surgeon, allowing a uniquely personal reflection on
management issues for patients with this rare condition.
Table IV. New tumors diagnosed in six patients during
follow-up after prior resection of carotid body tumor
(CBT)
Tumor type No. diagnosed
Adrenal tumor 4
Phaeochromocytoma 3
Adenoma 1
Vagal paraganglioma 4
Stellate ganglion paraganglioma 1
Glomus jugulare tumor 2
New contralateral CBT 1This series had a high incidence of familial CBT (30%)
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was evenmore evident in those with bilateral tumors (80%),
a finding that has also been reported by other groups.7
Other non-CBT paragangliomas must be excluded in these
patients with familial CBT, because 75% also had concur-
rent vagal tumors as well as other synchronous and meta-
chronous tumors. Because of this, we recommend screen-
ing of all family members of patients who have bilateral
CBTs or other neuroendocrine tumors.
Most of the tumors in our series presented as a painless neck
mass, as has been reported by others.3,8 Because somepatients
will present with cranial nerve palsies and because of the risk
of operative cranial nerve injury, it is imperative to carefully
assess and document the patient’s cranial nerve status pre-
operatively. Preoperative neurologic involvement generally
indicates more challenging surgery as well as the likelihood
of increased complications. In the presence of a clear pre-
existing neurologic deficit or when the likelihood of oper-
ative neurologic injury is highest, such as with recurrent or
bilateral tumors and in large tumors where more difficult
dissection can be anticipated with greater accompanying
risk to the surrounding nerves, more rigorous assessment
should be undertaken. This involves formal otolaryngology
review and indirect laryngoscopy, which might uncover
vocal cord palsy. Some surgeons advocate more rigorous
assessment for all cases, but this is not part of our standard
workup for small and uncomplicated tumors.
The tumors are highly vascular, and the experience of
the patient who hemorrhaged severely after fine-needle
aspiration biopsy—a procedure that we would not
recommend—is testament to the danger of performing a
biopsy of these tumors. If CBT is suspected clinically,
appropriate imaging almost always will confirm the diagno-
sis. Typically, a CBT causes splaying of the carotid bifurca-
tion that can be observed on diagnostic imaging. Early in
our series, angiography was used routinely before under-
taking tumor resection. With the advances in DUS and CT
imaging, angiography is no longer required for diagnosis,
and in our hands, is rarely performed for preoperative
planning. Color DUS imaging can usually provide informa-
tion about the vascularity of the tumor, its dimensions, and
its location in relation to the carotid bifurcation. Modern
CT or magnetic resonance imaging (MRI) can provide
definitive imaging for preoperative planning, including in-
formation about tumor extent as well as predicting vessel
wall involvement. Angiography may be used in instances
where ICA ligation may be required to perform a preoper-
ative balloon occlusion test.
Preoperative embolization was initially introduced to
decrease the size and vascularity of large tumors and is
advocated by some authors as being extremely important to
avoid major surgical complications for high-risk large
Shamblin group 2 or 3 tumors. It has also been used to treat
midsized tumors.9 No preoperative embolization was used
in any of the patients in this series, and we question its role.
Proponents advocate preoperative embolization, preferably
the day before the resection, thus avoiding any inflamma-
tion that may occur with waiting10 and claim the benefits ofa reduction in the technical difficulty of the procedure,
reduced operative time, reduced bleeding, reduced opera-
tive cranial nerve morbidity, and decreased length of hos-
pital stay.11-14 Other authors have found no benefit,9 and
most importantly, embolization is associated with a defin-
able neurologic complication rate, reported to be as high as
18% in one series.9,11,15 We are not convinced that the
perceived but unproven benefits of preoperative emboliza-
tion outweigh the potential complications. In our series of
49 procedures, bleeding requiring transfusion was encoun-
tered in only one patient at two separate procedures. On
neither occasion was bleeding related to tumor vascularity.
Endocrine assessment was undertaken selectively in a
small number of patients whose symptoms raised the pos-
sibility of functional tumors. None of the CBTs tested had
evidence of endocrine function. Routine testing of all pa-
tients is common practice in some centers, but our experi-
ence suggests that such an approach is not warranted. We
do recommend additional imaging of the abdomen and
chest with CT, MRI, or iodine-131-meta-iodobenzylgua-
nidine (MIBG) scintigraphy in patients with familial, mul-
tiple, or functional paragangliomas. A better test when the
tumor is nonfunctional is a pentetreotide scan, which uses a
radiolabelled somatostatin analogue.16,17 This scan is based
on the tumor containing somatostatin receptors. In addi-
tion to detecting small tumors, these studies can be useful
in evaluating residual or recurrent tumor and possible
metastasis.17,18
A CBT classification system proposed by Shamblin19 is
extensively used when describing these tumors. Shamblin
suggested a surgical classification of CBTs into three
groups according to the gross tumor-vessel relationship,
the intraoperative findings, and the postoperative specimen
examination. Advances in imaging have led to attempts to
assign this classification preoperatively; however, some au-
thors have stated that CBTs can only be given a Shamblin
classification at or after surgery.20A recent small study of
nine CBTs suggested that MRI can accurately predict
Shamblin group preoperatively, and the maximum degree
of circumferential contact of the CBTwith the ICA on axial
images is the criterion to predict the Shamblin group. In
that study, tumor size and Shamblin group did not have a
uniformly predictable relationship.21 Some have found the
size of the tumor is more useful when considering risk of
surgery22-24 because the Shamblin group classification is
only useful in predicting vascular morbidity and not neu-
rologic morbidity.20 The tumors in our series were not
assigned a Shamblin classification. Tumor volume was mea-
sured in 40 cases (85%) with CT and from the resected
specimens. Volume was significantly larger in those cases in
which nerve palsies occurred (52.2 vs 16.1 cm3; P  .05).
Alternative surgical strategies have been proposed for
the resection of CBT. The traditional surgical approach
commences at the bifurcation,24 but we believe this is more
likely to result in vessel injury and hemorrhage, making the
surgery more difficult. We recommend early control, but
not clamping of the CCA proximal to the lesion, followed
by dissection at the distal extent of the ICA, if possible, and
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rotid bifurcation dissection until last. In our experience,
this “craniocaudal” approach results in a low risk to the
vessels and minimal bleeding. Others have also advocated
this approach.25 The early identification of neural struc-
tures is paramount. By staying close to the tumor and
dissecting posteriorly around the ICA, identification of the
superior laryngeal nerve can be made early. This can be
difficult to identify with an anteromedial approach to the
ECA. The vagus nerve, which may be enlarged or edema-
tous with large perineural vessels—even when not directly
involved—is best identified away from the tumor area and
followed into the area of dissection. This minimizes risk of
injury from direct trauma, but retraction injury can still
occur.
Early in our series, partial resection of the vagus nerve
during removal of vagus vagale tumors was undertaken in
an attempt to preserve nerve function. This approach has
been abandoned because palsy almost always occurs and
there is a risk of inadequate resection of the tumor. For this
reason, we now recommend complete nerve resection for
these cases. Patients need to be carefully counseled about
the consequences of vagal palsy, which can be a very debil-
itating injury, with slow adjustment to the debility over
many months to years.
In patients with bilateral tumors, consideration of po-
tential neural dysfunction should be taken into account
when planning which side to resect first. The approach in
the earlier years of this series was to deal with the larger
tumor first and stage the resection of the contralateral
smaller tumor. Our policy has changed in the latter years.
Now, our strategy is to resect the smaller tumor first
because this can generally be done with minimal or only
temporary risk of cranial nerve injury. This allows the later,
staged removal of the larger tumor, where the risk of nerve
injury is greater, to be undertaken without the risk of
leaving the patient with bilateral nerve palsies.
Malignancy is rare in CBTs, thought to occur in
6%.26,27 Malignant potential is not readily determined,
however, and only the discovery of neural crest cells in
nonneuroendocrine sites is diagnostic. Compression or
erosion of local structures may result in nonresectability but
not true malignancy, as suggested by some authors.28-31
We documented a 15% malignancy rate in our series, and
we believe this is higher than reported by some authors17,32
because of our practice of routine excision of surrounding
abnormal lymph nodes. For this reason, we advocate the
excision of any large or closely approximated lymph nodes
for definitive histology in patients undergoing tumor resec-
tion because unsuspected micrometastasis may well be
present.
Cranial nerve deficits have been reported to occur in
11% to 49% after CBT resection.23,32-34 Unexpected cra-
nial nerve palsies occurred after CBT resection in 11 oper-
ations (22%) in our series, and 54% of these were perma-
nent. Cranial nerve palsy occurred more often in those
patients with large tumors than in those with smaller tu-
mors, and because of the increased nerve injury rate withlarge tumors as well as the potential for malignancy (albeit
low), we advocate an aggressive approach to early resection
unless there are compelling contraindications to surgery.
CONCLUSIONS
During the 25-year period during which 49 procedures
were performed on 39 patients with carotid body paragan-
glioma, some changes in management and strategy evolved
as technologies developed and experience accumulated.
From this experience, we draw the following conclusions:
● Routine diagnostic and planning angiography is obso-
lete and has been replaced with high-definition CT and
MRI. More sophisticated and functional imaging now
allows detection of smaller and multiple cervical tu-
mors and should be used in patients with familial,
bilateral, or functional paragangliomas.
● Endocrine function in cervical paragangliomas is rare,
and we therefore favor a selective approach to endo-
crine testing for patients in whom symptoms suggest
function rather than routine endocrine testing for all.
● Early surgical resection while the CBT is small is rec-
ommended to limit the rate of permanent neurologic
disability, which increases dramatically with larger tu-
mors. Where tumors are bilateral, we recommend re-
section of the smaller tumor first, followed by later
staged resection of the larger tumor, which has higher
operative risk.
● When confronted with VP, we favor complete resec-
tion of the nerve rather than partial removal, which in
our hands is associated uniformly with vagal palsy and
a high risk of recurrence.
● We have found no need for preoperative embolization
and remain unconvinced that its touted benefits out-
weigh the inherent stroke risk.
● We are comfortable with a craniocaudal method of
resection, which in our hands allows safe resection
of most tumors with minimal blood loss and low
morbidity.
● Because of the risk of unsuspected micrometastasis,
any large or closely adjacent lymph nodes should be
excised for definitive histology.
● Ongoing surveillance is mandatory in familial cases or
in patients with bilateral tumors because they are at
higher risk of having metachronous tumors and they
may represent the first of a new genetic line. Patients
with incomplete resections should also have ongoing
surveillance for the assessment of tumor enlargement.
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This single center, retrospective study adds some important
caveats to the scant clinical knowledge relating to the approach of
patients with carotid body tumors (CBT) or paragangliomas.
CBTs are known to occur in either sporadic or familial cases, the
latter resulting from a mutation of the succinate dehydrogenase
gene with a greater phenotypic penetration when altitude or
hypoxia is present.1 In patients with CBT, it has therefore been
customary to empirically recommend the careful evaluation for
multifocal disease and screen patient families to identify latenthas provided clear evidence to support the benefit of this
practice.
Though the patients in this study were not genetically evalu-
ated, the data nicely elucidate the relevance of a field defect in the
glomus cells of the paragangliomas. The identification in the study
of concurrent vagal paragangliomas (15%) or concurrent bilateral
CBT (21%) emphasizes the synchronous nature of the disease, and
the importance of bilateral neck evaluation withDuplex ultrasound
or contrast computed tomography. However, this study took this
a step further with careful evaluation of the proband’s family
